行情

CNAT

CNAT

Conatus制药
NASDAQ

实时行情|Nasdaq Last Sale

0.3800
+0.0078
+2.10%
交易中 12:15 12/10 EST
开盘
0.3700
昨收
0.3722
最高
0.3900
最低
0.3676
成交量
36.57万
成交额
--
52周最高
3.080
52周最低
0.2500
市值
1,260.48万
市盈率(TTM)
-0.9832
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CNAT 新闻

  • 报告:6家硅谷巨头过去10年全球避税1000亿美元
  • 新浪科技.12/03 10:17
  • 报告:秘鲁2019年三季度倒闭公司数量同比增五成
  • 中国新闻网.12/03 10:16
  • 英国保守党支持率较工党的领先优势扩大至12个百分点
  • 新浪财经综合.12/03 10:15
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.12/03 09:56

更多

所属板块

生物技术和医学研究
+0.63%
制药与医学研究
+0.66%

热门股票

名称
价格
涨跌幅

CNAT 简况

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
展开

Webull提供Conatus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。